The Real Price of AbbVie Stock Is Cheaper Than You Think

AbbVie (ABBV) stock appears expensive at first glance with a high price-to-earnings multiple, but a deeper analysis reveals it's cheaper than it seems. When factoring in expected earnings by 2027, the stock's valuation drops significantly due to anticipated growth. This "forward discount" is driven by expanding profit margins and strong performance from its immunology drugs, offering a margin of safety for patient investors.